mSEPT9 performs better than CEA in NAT response and MRD assessment and recurrence prediction of stage III CRC.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-04-08 DOI:10.1080/17520363.2025.2489919

Jianbiao Xu, Yun Shang, Tongmin Wang, Jianlin Song, Wenchuan Zhu, Yunjun Zeng, Jianxun Wang, Li Zhang, Xiaochun Yang

{"title":"mSEPT9 performs better than CEA in NAT response and MRD assessment and recurrence prediction of stage III CRC.","authors":"Jianbiao Xu, Yun Shang, Tongmin Wang, Jianlin Song, Wenchuan Zhu, Yunjun Zeng, Jianxun Wang, Li Zhang, Xiaochun Yang","doi":"10.1080/17520363.2025.2489919","DOIUrl":null,"url":null,"abstract":"Aims: This study aimed to investigate the capability of methylated SEPT9 (mSEPT9) assay in assessing the neoadjuvant therapy (NAT) response,the minimal residual disease (MRD) and predicting the recurrence of stage III colorectal cancer (CRC).Materials & methods: We prospectively recruited 124 stage III CRC patients. All patients received pre-surgical NAT and subsequent curative surgery, and were followed up to 627 days. Blood samples were collected before NAT, after NAT and after surgery. Measurements of mSEPT9 and CEA were performed.Results: mSEPT9 exhibited a positive detection rate (PDR) of 82.6% for stage III CRC, significantly higher than that of the carcinoembryonic antigen (CEA) (60.3%,p < 0.001). The levels of mSEPT9 and CEA significantly decreased after NAT. This can be observed for patients with complete response (CR), partial response (PR), stable disease (SD) and tumor regression grade (TRG) 1-3 in mSEPT9 and patients with PR, SD and TRG 2-3 in CEA. Stepwise percentage decrease of marker levels was more prominent in mSEPT9 than in CEA following NAT and surgical treatment. Kaplan-Meier analysis suggested that mSEPT9 significantly stratified the patient recurrence-free survival(RFS) before NAT, after NAT and after surgery. In contrast, CEA significantly stratified RFS after NAT and after surgery, while CEA levels before NAT did not significantly stratify RFS.Conclusion: mSEPT9 exhibits better applicability than CEA in assessment in terms of patient coverage, sensitivity and the pre-NAT recurrence prediction.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-12"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2489919","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: This study aimed to investigate the capability of methylated SEPT9 (mSEPT9) assay in assessing the neoadjuvant therapy (NAT) response,the minimal residual disease (MRD) and predicting the recurrence of stage III colorectal cancer (CRC).

Materials & methods: We prospectively recruited 124 stage III CRC patients. All patients received pre-surgical NAT and subsequent curative surgery, and were followed up to 627 days. Blood samples were collected before NAT, after NAT and after surgery. Measurements of mSEPT9 and CEA were performed.

Results: mSEPT9 exhibited a positive detection rate (PDR) of 82.6% for stage III CRC, significantly higher than that of the carcinoembryonic antigen (CEA) (60.3%,p < 0.001). The levels of mSEPT9 and CEA significantly decreased after NAT. This can be observed for patients with complete response (CR), partial response (PR), stable disease (SD) and tumor regression grade (TRG) 1-3 in mSEPT9 and patients with PR, SD and TRG 2-3 in CEA. Stepwise percentage decrease of marker levels was more prominent in mSEPT9 than in CEA following NAT and surgical treatment. Kaplan-Meier analysis suggested that mSEPT9 significantly stratified the patient recurrence-free survival(RFS) before NAT, after NAT and after surgery. In contrast, CEA significantly stratified RFS after NAT and after surgery, while CEA levels before NAT did not significantly stratify RFS.

Conclusion: mSEPT9 exhibits better applicability than CEA in assessment in terms of patient coverage, sensitivity and the pre-NAT recurrence prediction.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.